Award

Adiponectin ameliorates chronic hypoperfusion induced vascular dementia

Description: Vascular contributions and cognitive impairment and dementia (VCID) is the second most common form of dementia after Alzheimer's disease (AD) and has no curative treatments thus far. It encompasses a range of cognitive deficits caused by cerebrovascular abnormalities and subsequent cerebral hypoperfusion. The pathological alterations of VCID are multifaceted, and blood-brain barrier (BBB) impairment is a crucial pathological hallmark of VCID that significantly contributes to cognitive deficits. Therefore, BBB protection remains a promising strategy for VCID prevention. Emerging evidence indicates that chronic metabolic dysregulation may trigger or amplify harmful signaling pathways in the brain and lead to cognitive impairments. Adiponectin is a 30 kDa adipokine produced by adipocytes and plays a critical role in glucose metabolism and fatty acid oxidation. Population-based, clinical, and preclinical studies suggest the roles of adiponectin in regulating CNS diseases including AD, stroke, and mood disorders. Our recent study found that the adiponectin/adiponectin receptor(adipoR) system is activated in a mouse model of asymmetric common carotid artery stenosis (ACAS)-induced chronic cerebral hypoperfusion. We further obtained exciting data showing that 1) Adiponectin knockout (KO) mice exhibited worse cognitive deficits in the Morris water maze test after ACAS. 2) AdipoR1/R2 are highly expressed on endothelial cells. 3) AdipoRon, a small molecule agonist of adiponectin receptors, reduced the BBB leakage in the in vivo ACAS model and in an in vitro BBB model. 4) AdipoRon treatment reduced NF-kB activation in an in vitro BBB model. 5) AdipoRon treatment improved cognitive functions after ACAS. Collectively, we will test the central hypothesis that adiponectin ameliorates BBB impairment and cognitive deficits in chronic cerebral hypoperfusion-induced VCID by regulating endothelium inflammation. There are three specific aims: 1) To assess if adiponectin protects BBB integrity and prevents cognitive deficits upon chronic hypoperfusion; 2) To determine whether adiponectin alleviates endothelium inflammation via inhibiting the activation of NF-kB pathway in ECs, and 3) To verify that adipoRon treatment enhances BBB integrity and long-term cognitive functions after ACAS in aged mice of both sexes. The long-term goal of the proposed studies is to develop a novel, clinically feasible approach to improve long-term cognitive recovery after VCID.
Amount: $231,000
Funding type: fellowship
Funder scheme: Career Development Award
Start date: 2022-04-01
End date: 2025-03-31
Investigator: Hongjian Pu (lead)
Subfield: Neurology
Funded outputs count: 1
Funder award ID: 926806
OpenAlex ID: G1722736283
2026 · Chenghao Jin, Li Fan, et al. · bioRxiv (Cold Spring Harbor Laboratory)